Technologies for enhanced efficacy of DNA vaccines

Authors: Saade, Fadi; Petrovsky, Nikolai

Source: Expert Review of Vaccines, Volume 11, Number 2, February 2012 , pp. 189-209(21)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Despite many years of research, human DNA vaccines have yet to fulfill their early promise. Over the past 15 years, multiple generations of DNA vaccines have been developed and tested in preclinical models for prophylactic and therapeutic applications in the areas of infectious disease and cancer, but have failed in the clinic. Thus, while DNA vaccines have achieved successful licensure for veterinary applications, their poor immunogenicity in humans when compared with traditional protein-based vaccines has hindered their progress. Many strategies have been attempted to improve DNA vaccine potency including use of more efficient promoters and codon optimization, addition of traditional or genetic adjuvants, electroporation, intradermal delivery and various prime-boost strategies. This review summarizes these advances in DNA vaccine technologies and attempts to answer the question of when DNA vaccines might eventually be licensed for human use.

Keywords: adjuvant; cytokine; DNA; electroporation; immunization; plasmid; vaccine

Document Type: Research article

DOI: http://dx.doi.org/10.1586/erv.11.188

Affiliations: 1: 1Vaxine Pty Ltd, Bedford Park, Adelaide 5042, Australia

Publication date: 2012-02-01

More about this publication?

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites